Acurx Pharmaceuticals, Inc.
ACXP
$0.335
$0.0051.52%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.31% | -8.07% | 34.37% | 49.57% | 73.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.61% | -9.42% | 19.64% | 50.81% | 56.87% |
| Operating Income | 45.61% | 9.42% | -19.64% | -50.81% | -56.87% |
| Income Before Tax | 45.61% | 9.42% | -19.64% | -50.81% | -56.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.61% | 9.42% | -19.64% | -50.81% | -56.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.61% | 9.42% | -19.64% | -50.81% | -56.87% |
| EBIT | 45.61% | 9.42% | -19.64% | -50.81% | -56.87% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 55.53% | 28.02% | 7.85% | -13.43% | -31.59% |
| Normalized Basic EPS | 55.54% | 27.99% | 7.87% | -13.41% | -31.62% |
| EPS Diluted | 55.53% | 28.02% | 7.85% | -13.43% | -31.59% |
| Normalized Diluted EPS | 55.54% | 27.99% | 7.87% | -13.41% | -31.62% |
| Average Basic Shares Outstanding | 22.32% | 25.82% | 29.85% | 32.93% | 19.20% |
| Average Diluted Shares Outstanding | 22.32% | 25.82% | 29.85% | 32.93% | 19.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
